Aptar Pharma, part of Aptargroup Inc., has established a technical collaboration with Covirix Medical Pty Ltd. under a letter of intent to develop inhaled antiviral treatments.
Newcelx Ltd. has entered into a collaborative research agreement with Eledon Pharmaceuticals Inc. with the aim of advancing its lead program, NCEL-101, for type 1 diabetes.
Zelluna ASA has established a collaboration with Etcembly Ltd. that will focus on the engineering of high-affinity, tumor-specific T-cell receptors targeting KKLC1.
